Explorative Open Phase II-study, Food Allergy Suppression Therapy During Protection With Xolair
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2018
At a glance
- Drugs Omalizumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Acronyms FASTX
- 23 Aug 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020.
- 23 Aug 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2020.
- 08 Jan 2018 New trial record